{"generic":"Ibrutinib","drugs":["Ibrutinib","Imbruvica"],"mono":{"0":{"id":"930819-s-0","title":"Generic Names","mono":"Ibrutinib"},"1":{"id":"930819-s-1","title":"Dosing and Indications","sub":[{"id":"930819-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Chronic lymphoid leukemia, In patients who have received at least 1 prior therapy:<\/b> 420 mg ORALLY daily at the same time each day<\/li><li><b>Chronic lymphoid leukemia, In patients with 17p chromosome deletion:<\/b> 420 mg ORALLY daily at the same time each day<\/li><li><b>Mantle cell lymphoma, In previously treated patients:<\/b> 560 mg ORALLY once daily at the same time each day<\/li><li><b>Waldenstroem macroglobulinemia:<\/b> 420 mg ORALLY once daily<\/li><\/ul>"},{"id":"930819-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy in pediatric patients not established "},{"id":"930819-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Hepatic impairment, mild (Child-Pugh class A):<\/b> Reduce dose to 140 mg\/day<\/li><li><b>Hepatic impairment, moderate or severe (Child-Pugh class B or C):<\/b> Avoid use<\/li><li><b>Concomitant moderate CYP3A inhibitor:<\/b> Reduce the ibrutinib dose to 140 mg\/day<\/li><li><b>Concomitant strong CYP3A inhibitor administered for 7 or fewer days:<\/b> Consider interrupting ibrutinib therapy until the CYP3A inhibitor is no longer necessary; use of a strong CYP3A inhibitor requiring chronic administration is not recommended.<\/li><li><b>Hematologic events (grade 4):<\/b> Interrupt and resume at the starting dose upon resolution to grade 1 or baseline; if toxicity reoccurs, reinitiate at a dose reduced by 140 mg\/day; with a third reoccurrence, reinitiate at a second reduction of 140 mg\/day; if toxicities persist or recur following 2 dose reductions, discontinue therapy .<\/li><li><b>Neutropenia with infection or fever (grade 3 or greater):<\/b> Interrupt and resume at the starting dose upon resolution to grade 1 or baseline; if toxicity reoccurs, reinitiate at a dose reduced by 140 mg\/day; with a third reoccurrence, reinitiate at a second reduction of 140 mg\/day; if toxicities persist or recur following 2 dose reductions, discontinue therapy.<\/li><li><b>Nonhematologic adverse events (grade 3 or greater):<\/b> Interrupt and resume at the starting dose upon resolution to grade 1 or baseline; if toxicity reoccurs, reinitiate at a dose reduced by 140 mg\/day; with a third reoccurrence, reinitiate at a second reduction of 140 mg\/day; if toxicities persist or recur following 2 dose reductions, discontinue therapy.<\/li><li><b>Surgery:<\/b> Consider interruption of ibrutinib therapy for at least 3 to 7 days prior to and after surgery, depending on the surgery type and bleeding risk.<\/li><\/ul>"},{"id":"930819-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Chronic lymphoid leukemia, In patients who have received at least 1 prior therapy<\/li><li>Chronic lymphoid leukemia, In patients with 17p chromosome deletion<\/li><li>Mantle cell lymphoma, In previously treated patients<\/li><li>Waldenstroem macroglobulinemia<\/li><\/ul>"}]},"3":{"id":"930819-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930819-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"930819-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Atrial fibrillation and atrial flutter have occurred, particularly among patients with acute infection or a history of atrial fibrillation or cardiac risk factors; monitoring recommended; dose adjustment or discontinuation may be required<\/li><li>Dermatologic:<\/li><li>-- Second primary malignancies, including skin cancer and other carcinomas, have been reported<\/li><li>Hematologic:<\/li><li>-- Serious, sometimes fatal, bleeding events (ie, hemorrhage, subdural hematoma, gastrointestinal bleeding, hematuria) have occurred, especially with concurrent use of antiplatelets or anticoagulants<\/li><li>-- Serious cytopenias (ie, neutropenia, thrombocytopenia, anemia) have been reported; monitoring recommended<\/li><li>Hepatic:<\/li><li>-- Mild impairment requires dose adjustment and monitoring; avoid use in moderate or severe impairment<\/li><li>Immunologic:<\/li><li>-- Infection, including fatal cases, have been reported; monitoring recommended<\/li><li>Reproductive:<\/li><li>-- Avoid pregnancy during use; may cause fetal harm<\/li><li>Other:<\/li><li>-- Consider withholding treatment for at least 3 to 7 days before and after surgery, depending on the risk of bleeding<\/li><li>-- Tumor lysis syndrome has been reported; monitoring recommended; take precautions in patients with increased risk<\/li><li>-- Patients aged 65 and older at increased risk for serious adverse effects (eg, atrial fibrillation, hypertension, pneumonia, cellulitis, diarrhea, dehydration)<\/li><li>Concomitant Use:<\/li><li>-- Avoid concomitant use of strong or moderate CYP3A inhibitors, including grapefruit and Seville oranges; if clinically required, monitoring indicated with possible dose reduction or interruption<\/li><li>-- Avoid concomitant use of strong CYP3A inducers (ie, carbamazepine, rifampin, phenytoin, St John's wort)<\/li><\/ul>"},{"id":"930819-s-3-11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"930819-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930819-s-4","title":"Drug Interactions","sub":[{"id":"930819-s-4-13","title":"Contraindicated","mono":"<ul><li>Atazanavir (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><\/ul>"},{"id":"930819-s-4-14","title":"Major","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Diltiazem (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fosamprenavir (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Verapamil (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"}]},"5":{"id":"930819-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Peripheral edema (23% to 35%)<\/li><li><b>Dermatologic:<\/b>Rash (22% to 27%)<\/li><li><b>Endocrine metabolic:<\/b>Increased uric acid level (40%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (15% to 24%), Constipation (15% to 25%), Decrease in appetite (17% to 21%), Diarrhea (37% to 63%), Nausea (21% to 31%), Stomatitis (16% to 21%), Vomiting (14% to 23%)<\/li><li><b>Hematologic:<\/b>Bleeding (50%), Contusion (11% to 54%), Decreased hemoglobin, All grades (13%% to 44%), Decreased platelet count, All grades (43% to 71%), Neutropenia, All grades (44% to 54%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (11% to 23%), Musculoskeletal pain (27% to 37%), Spasm (14% to 21%)<\/li><li><b>Neurologic:<\/b>Dizziness (11% to 21%)<\/li><li><b>Respiratory:<\/b>Dyspnea (10% to 27%), Sinusitis (11% to 21%), Upper respiratory infection (16% to 48%)<\/li><li><b>Other:<\/b>Fatigue (28% to 41%), Fever (18% to 25%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Atrial fibrillation, Grade 3 or 4, Atrial flutter, Grade 3 or 4<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage, Grade 3 or 4<\/li><li><b>Hematologic:<\/b>Bleeding, Grade 3 or higher (Up to 6%), Decreased hemoglobin, Grade 3 or 4 (0% to 9%), Decreased platelet count, Grade 3 or 4 (5% to 17%), Neutropenia, Grade 3 or 4 (19% to 29%), Subdural hematoma<\/li><li><b>Renal:<\/b>Hematuria, Renal failure<\/li><li><b>Respiratory:<\/b>Pneumonia (10% to 15%)<\/li><li><b>Other:<\/b>Infectious disease, Grade 3 or higher (25% to 26%), Secondary malignant neoplastic disease (5% to 14%)<\/li><\/ul>"},"6":{"id":"930819-s-6","title":"Drug Name Info","sub":{"0":{"id":"930819-s-6-17","title":"US Trade Names","mono":"Imbruvica<br\/>"},"2":{"id":"930819-s-6-19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Tyrosine Kinase Inhibitor<\/li><\/ul>"},"3":{"id":"930819-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930819-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930819-s-7","title":"Mechanism Of Action","mono":"Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that interferes with malignant B-cell proliferation and survival (in vivo), as well as cell migration and substrate adhesion (in vitro).<br\/>"},"8":{"id":"930819-s-8","title":"Pharmacokinetics","sub":[{"id":"930819-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 1 to 2 hours<\/li><li>Effects of food: 2- to 4-fold increase in Cmax; 2-fold increase in AUC<\/li><\/ul>"},{"id":"930819-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: 97.3%<\/li><li>Vd: 10,000 L<\/li><\/ul>"},{"id":"930819-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: extensive<\/li><li>PCI-45227: active<\/li><li>inhibitor of P-glycoprotein (P-gp) in the gastrointestinal tract due to higher local concentrations following an oral dose; unlikely to be a P-gp inhibitor systemically at therapeutic doses<\/li><li>substrate of CYP3A4 (primary) and CYP2D6 (minor)<\/li><\/ul>"},{"id":"930819-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 80% metabolites; 1% unchanged<\/li><li>Renal: 20% metabolites; 0% unchanged<\/li><li>Renal clearance: less than 10%<\/li><li>Total body clearance: 1000 L\/hr (fed state); 2000 L\/hr (fasted state)<\/li><\/ul>"},{"id":"930819-s-8-27","title":"Elimination Half Life","mono":"4 to 6 hours <br\/>"}]},"9":{"id":"930819-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>Swallow capsules whole with water; do not open, break, or chew <br\/>"},"10":{"id":"930819-s-10","title":"Monitoring","mono":"<ul><li>Evidence of disease response or stabilization is indicative of efficacy<\/li><li>CBC; monthly during treatment; including differential<\/li><li>Bleeding; during therapy<\/li><li>Fever or signs of infection, especially in elderly patients<\/li><li>Atrial fibrillation; periodically, especially in elderly patients<\/li><li>Patients at risk for tumor lysis syndrome<\/li><\/ul>"},"11":{"id":"930819-s-11","title":"How Supplied","mono":"<b>Imbruvica<\/b><br\/>Oral Capsule: 140 MG<br\/>"},"13":{"id":"930819-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient to report symptoms of an infection or hemorrhage.<\/li><li>Tell patient to report symptoms of atrial fibrillation or flutter.<\/li><li>Advise patient to report symptoms of tumor lysis syndrome.<\/li><li>Side effects may include nausea, abdominal pain, vomiting, constipation, upper respiratory tract infection, fatigue, bruising, rash, musculoskeletal pain, and peripheral edema.<\/li><li>Tell patient to maintain adequate hydration and to report persistent diarrhea.<\/li><li>Counsel patient to report any new skin lesions.<\/li><li>Instruct patient to avoid grapefruit products and Seville oranges.<\/li><li>Advise patient to take a missed dose as soon as possible on the same day and to resume a normal dosing schedule.<\/li><\/ul>"}}}